Table 1 Demographic profile of the study cohort.
From: Iron-Overload triggers ADAM-17 mediated inflammation in Severe Alcoholic Hepatitis
Parameters | Discovery cohort | Validation cohort | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
(A) | (B) | (A) vs (B) | (C) | (D) | (E) | (C) vs (D) | (C) vs (E) | (F) | (G) | (F) vs. (G) | |
Gr.A: SAH-IO(n = 5) | Gr.B:SAH-NIO(n = 9) | p-value | SAH (n = 100) | Alcoholic Cirrhosis (n = 20) | Healthy controls (n = 20) | p-value | p-value | SAH Non-survivors(n = 56) | SAH Survivors (n = 44) | p-value | |
M:F | 5:00 | 9:01 | — | 92:08:00 | 18:02 | 16:04 | — | — | 51:05:00 | 41:03:00 | — |
Age (yrs.) | 41 (30–55) | 40 (20–60) | — | 43 (19–66) | 35 (28–57) | 33 (30–40) | — | — | 43 (38–57) | 40 (28–65) | — |
TLC (×103/mm3) | 9.5 (6.0–18) | 13 (8.9–20) | 0.0012 | 9.5 (3.9–29.8) | 8.3 (3.1–20) | 9.6 (4–11) | 0.022 | — | 10.7 (5.0–28) | 11.5 (3.9–23.7) | 0.2776 |
Platelet (×103/mm3) | 95 (48–154) | 135 (110–180) | 0.011 | 126 (45–260) | 171 (60–300) | 155 (135–400) | 0.015 | 0.031 | 100 (45–240) | 120 (50–260) | 0.0852 |
Bilirubin (mg/dL) | 29 (15–42) | 15 (6.8–20) | <0.01 | 23.30 (6.8–43) | 1.5 (0.9–34) | 0.9 (0.5–1.5) | <0.01 | <0.01 | 26 (9–43) | 21 (6.8–27) | 0.0026 |
INR | 2.8 (1.9–4.1) | 2.1 (1.5–2.5) | <0.01 | 2.5 (1.1–4.6) | 1.3 (1–2.5) | 0.9 (0.8–1.2) | <0.01 | <0.01 | 2.3 (1.5–4.6) | 2.2 (1.1–4.0) | 0.0573 |
ALT (IU/L) | 110 (75–252) | 65 (35–150) | 0.004 | 69 (22–339) | 60 (33–300) | 27 (18–45) | 0.052 | 0.021 | 96 (25–339) | 51 (22–250) | 0.0017 |
Albumin (gm/dL) | 2.3 (2.1–3.7) | 2.6 (2.1–4.5) | 0.022 | 2.1 (1.8–4.9) | 2.6 (2.9–4.6) | 4 (3.4–5.4) | 0.048 | 0.0112 | 2.5 (2.0–4.9) | 2.6 (1.8–3.1) | 0.8237 |
Serum creatinine (mg/dL) | 2.2 (1.5–5.8) | 0.8 (0.4–2.5) | <0.001 | 2.4 (0.4–6.2) | 0.75 (0.1–0.9) | 0.7 (0.6–0.9) | <0.01 | <0.01 | 2.3 (0.7–6.2) | 0.6 (0.4–2.9) | < 0.01 |
HE at baseline | (80%),3 (0–4) | (20%), 1 (0–3) | — | (85%), 2 (0–4) | — | — | — | — | (72%),2 (0–4) | (25%), 0(0–3) | 0.001 |
Na (mEq/L) | 130 (116–138) | 131 (120–140) | 0.12 | 131 (115–149) | 133 (132–141) | 136 (135–140) | 0.08 | 0.048 | 130 (115–149) | 131 (124–139) | 0.2784 |
Serum Iron (ug/ml) | 1100 (750–2512) | 295 (150–680) | 0.0001 | 446.2 (109.4–2644) | 344.1 (106.3–862.5) | 114.1 (40.63–243.8) | 0.04 | 0.012 | 856.9 (109.4–2644) | 312.5 (109.4–1134) | < 0.001 |
Serum Ferritin (ug/ml) | 754 (390–1123) | 450 (59–1100) | 0.01 | 602.5 (158–1318) | 104 (59.44–745.1) | 113.7 (39.83–554.4) | 0.01 | 0.01 | 632.1 (158–1318) | 461.9 (61.7–1157) | 0.0156 |
Soluble CD163 (ng/ml) | 1855 (1295–2216) | 500 (200–800) | <0.01 | 1150 (220–2216) | 550 (370–760) | 495 (125–610) | <0.01 | <0.01 | 1583 (595–2216) | 590 (180–1235) | < 0.01 |
Hemoglobin-Haptoglobin complex (ng/ml) | 1.8 (1.4–5) | 6 (1.5–20) | <0.01 | 3 (1.4–23.2) | 13.25 (4–26) | 13.75 (8–25) | <0.01 | <0.01 | 2 (1.4–20) | 4.5 (1.5–23.2) | 0.01 |
TNF-α (picogram/ml) | 100 (85–118) | 37 (28–70) | <0.001 | 68.5 (28–126) | 16 (4.6–45) | 8.5 (3–27) | <0.001 | <0.001 | 80 (28–118) | 39.5 (28–86) | < 0.001 |
DF score | 125 (70–243) | 87 (30–150) | <0.01 | 103 (30–243) | 16.5 (5.2–60) | — | <0.01 | — | 125 (47.6–243) | 87 (30–191) | 0.0137 |
CTP-Score | 14 (10–15) | 12 (4–13) | <0.01 | 12 (4–14) | 8 (5–13) | — | <0.01 | — | 14 (9–14) | 13 (4–14) | 0.0429 |
MELD-Score | 35 (27–40) | 25 (15–30) | <0.01 | 24 (12–40) | 12 (8–17) | — | <0.01 | — | 30 (12–40) | 29 (15–36) | 0.043 |
SOFA-Score | 10 (8–12) | 5 (4–7) | <0.01 | 7 (4–12) | 2 (1–2) | — | <0.01 | — | 8 (4–12) | 5 (4–8) | 0.001 |
Median Survival | — | — | — | — | — | — | — | — | 24 (7–60) | 130 (110–330) | 0.0001 |
